The post VanEck Exec Questions XRP’s Utility appeared on BitcoinEthereumNews.com. Matthew Sigel, the director of research for digital assets at VanEck, recently riled up the XRP community by implying that the popular altcoin does not actually have any utility.  “Dear XRP maxis, I may never understand what your ‘blockchain’ actually does, but I’ll always respect the passion required to pretend it does something,” Sigel said in a caustic social media post. In a follow-up post, he further questions whether there is real developer interest or meaningful applications being built on XRP, which is a common metric for a blockchain’s viability. Bitcoin comparison  He has also compared Bitcoin’s adoption by large, institutional actors and even governments to XRP’s relatively modest adoption. VanEck’s crypto expert has noted that retail investors like university endowments, sovereign wealth funds, and even a central bank have invested in Bitcoin.  You Might Also Like Moreover, a total of 12 countries are now mining Bitcoin with direct government support, which is due to the cryptocurrency’s synergies with the electrical grid. Retail investors like University Endowments, Sovereign Wealth Funds, and today a Central Bank. 12 countries are now mining Bitcoin with direct government support, thanks to its synergies with the electrical grid. Anyway by all means, invest away in XRP. I’m not stopping you. — matthew sigel, recovering CFA (@matthew_sigel) November 14, 2025 Pouring cold water on BlackRock collaboration After facing some pushback from the XRP Army, Sigel has also addressed Ripple’s collaborations (like with BlackRock and OntoFinance) and initiatives, questioning whether they actually benefit XRP holders financially. You Might Also Like He has listed economic mechanisms like transaction fees, revenue sharing, or token burns, arguing that XRP doesn’t have clear mechanisms linking its token price to the adoption of Ripple’s projects. Ignoring ETF hype  VanEck has been actively involved in crypto‑ETF filings for other assets. For example, it… The post VanEck Exec Questions XRP’s Utility appeared on BitcoinEthereumNews.com. Matthew Sigel, the director of research for digital assets at VanEck, recently riled up the XRP community by implying that the popular altcoin does not actually have any utility.  “Dear XRP maxis, I may never understand what your ‘blockchain’ actually does, but I’ll always respect the passion required to pretend it does something,” Sigel said in a caustic social media post. In a follow-up post, he further questions whether there is real developer interest or meaningful applications being built on XRP, which is a common metric for a blockchain’s viability. Bitcoin comparison  He has also compared Bitcoin’s adoption by large, institutional actors and even governments to XRP’s relatively modest adoption. VanEck’s crypto expert has noted that retail investors like university endowments, sovereign wealth funds, and even a central bank have invested in Bitcoin.  You Might Also Like Moreover, a total of 12 countries are now mining Bitcoin with direct government support, which is due to the cryptocurrency’s synergies with the electrical grid. Retail investors like University Endowments, Sovereign Wealth Funds, and today a Central Bank. 12 countries are now mining Bitcoin with direct government support, thanks to its synergies with the electrical grid. Anyway by all means, invest away in XRP. I’m not stopping you. — matthew sigel, recovering CFA (@matthew_sigel) November 14, 2025 Pouring cold water on BlackRock collaboration After facing some pushback from the XRP Army, Sigel has also addressed Ripple’s collaborations (like with BlackRock and OntoFinance) and initiatives, questioning whether they actually benefit XRP holders financially. You Might Also Like He has listed economic mechanisms like transaction fees, revenue sharing, or token burns, arguing that XRP doesn’t have clear mechanisms linking its token price to the adoption of Ripple’s projects. Ignoring ETF hype  VanEck has been actively involved in crypto‑ETF filings for other assets. For example, it…

VanEck Exec Questions XRP’s Utility

Matthew Sigel, the director of research for digital assets at VanEck, recently riled up the XRP community by implying that the popular altcoin does not actually have any utility. 

“Dear XRP maxis, I may never understand what your ‘blockchain’ actually does, but I’ll always respect the passion required to pretend it does something,” Sigel said in a caustic social media post.

In a follow-up post, he further questions whether there is real developer interest or meaningful applications being built on XRP, which is a common metric for a blockchain’s viability.

Bitcoin comparison 

He has also compared Bitcoin’s adoption by large, institutional actors and even governments to XRP’s relatively modest adoption.

VanEck’s crypto expert has noted that retail investors like university endowments, sovereign wealth funds, and even a central bank have invested in Bitcoin. 

You Might Also Like

Moreover, a total of 12 countries are now mining Bitcoin with direct government support, which is due to the cryptocurrency’s synergies with the electrical grid.

Pouring cold water on BlackRock collaboration

After facing some pushback from the XRP Army, Sigel has also addressed Ripple’s collaborations (like with BlackRock and OntoFinance) and initiatives, questioning whether they actually benefit XRP holders financially.

You Might Also Like

He has listed economic mechanisms like transaction fees, revenue sharing, or token burns, arguing that XRP doesn’t have clear mechanisms linking its token price to the adoption of Ripple’s projects.

Ignoring ETF hype 

VanEck has been actively involved in crypto‑ETF filings for other assets. For example, it filed to list a spot Solana (SOL) ETF in the U.S. 

However, VanEck did not apply to launch an XRP ETF, which puts it in the same camp with icy financial giants as Fidelity and BlackRock.

Source: https://u.today/vaneck-exec-questions-xrps-utility

Market Opportunity
XRP Logo
XRP Price(XRP)
$2.0636
$2.0636$2.0636
-1.56%
USD
XRP (XRP) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact service@support.mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Over $145M Evaporates In Brutal Long Squeeze

Over $145M Evaporates In Brutal Long Squeeze

The post Over $145M Evaporates In Brutal Long Squeeze appeared on BitcoinEthereumNews.com. Crypto Futures Liquidations: Over $145M Evaporates In Brutal Long Squeeze
Share
BitcoinEthereumNews2026/01/16 11:35
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26
Edges higher ahead of BoC-Fed policy outcome

Edges higher ahead of BoC-Fed policy outcome

The post Edges higher ahead of BoC-Fed policy outcome appeared on BitcoinEthereumNews.com. USD/CAD gains marginally to near 1.3760 ahead of monetary policy announcements by the Fed and the BoC. Both the Fed and the BoC are expected to lower interest rates. USD/CAD forms a Head and Shoulder chart pattern. The USD/CAD pair ticks up to near 1.3760 during the late European session on Wednesday. The Loonie pair gains marginally ahead of monetary policy outcomes by the Bank of Canada (BoC) and the Federal Reserve (Fed) during New York trading hours. Both the BoC and the Fed are expected to cut interest rates amid mounting labor market conditions in their respective economies. Inflationary pressures in the Canadian economy have cooled down, emerging as another reason behind the BoC’s dovish expectations. However, the Fed is expected to start the monetary-easing campaign despite the United States (US) inflation remaining higher. Investors will closely monitor press conferences from both Fed Chair Jerome Powell and BoC Governor Tiff Macklem to get cues about whether there will be more interest rate cuts in the remainder of the year. According to analysts from Barclays, the Fed’s latest median projections for interest rates are likely to call for three interest rate cuts by 2025. Ahead of the Fed’s monetary policy, the US Dollar Index (DXY), which tracks the Greenback’s value against six major currencies, holds onto Tuesday’s losses near 96.60. USD/CAD forms a Head and Shoulder chart pattern, which indicates a bearish reversal. The neckline of the above-mentioned chart pattern is plotted near 1.3715. The near-term trend of the pair remains bearish as it stays below the 20-day Exponential Moving Average (EMA), which trades around 1.3800. The 14-day Relative Strength Index (RSI) slides to near 40.00. A fresh bearish momentum would emerge if the RSI falls below that level. Going forward, the asset could slide towards the round level of…
Share
BitcoinEthereumNews2025/09/18 01:23